- Funding Set to Accelerate Clinical Development of Novel Medicines for Rare Central Nervous System Disorders -
Milan, Italy – April 30, 2015 – Newron Pharmaceuticals S.p.A. (“
Milan, Italy – 24 March 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel Central Nervous System (CNS) and pain therapies,
March 4, 2015 – Milan, Italy – Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS) and
Milan, Italy – March 4, 2015 - Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel Central Nervous System (CNS) and pain therapies,
Xadago® under review as an add-on therapy for patients with early- to late-stage Parkinson’s disease
PDUFA date by December 29, 2015
Milan, Italy, March 2, 2015 – Newron
The European Commission approves the use of XADAGO® as add-on to L-dopa alone or in combination with other PD medications in mid-late stage PD patients with motor fluctuations
February 5, 2015 – Milan, Italy – Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS)
Milan, Italy, January 15, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today the
Milan, Italy, January 15, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today the
Milan, Italy, January 14, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today the
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
